Skip to main content

Table 2 Results of the analysis of cases with or without overall nausea among 312 cases receiving palonosetron

From: Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens

  Cases with nausea Cases without nausea p value
Case number 66 (21.2%) 246 (78.8%)  
Age, mean ± SD 60.4 ± 12.6 65.2 ± 10.2 < 0.001
≥75 years, n (%) 5 (7.6) 42 (17.1) 0.05
≥70 years, n (%) 19 (28.8) 91 (37.0) 0.21
Sex, n (%) 28:38 120:126 0.35
(42.4:57.6) (48.8:51.2)
PS 0:1 + 2, n (%) 26:40 129:117 0.05
(39.4:60.6) (52.4:47.6)
Aprepitant, n (%) 50 (75.8) 165 (67.0) 0.17
Neut < 1000, n (%) 5 (7.6) 18 (7.3) 0.63
Hb < 10 mg/dl, n (%) 32 (48.5) 142 (57.7) 0.18
CRE ≥1.1 mg/dl, n (%) 7 (6,5) 7 (2.8) 0.07
ALT > 2.5 ULN, n (%) 17 (25.8) 38 (15.9) 0.05
Constipation, n (%) 28 (42.4) 70 (31.8) 0.03
Diarrhea, n (%) 19 (28.8) 48 (19.0) 0.10
Oral mucositis, n (%) 20 (30.3) 57 (20.8) 0.23
Neuropathy, n (%) 47 (71.2) 139 (53.6) 0.03
General fatigue, n (%) 49 (74.2) 113 (44.3) < 0.001
Pain NRS ≥1, n (%) 22 (33.3) 69 (31.5) 0.40
L-OHP, n (%) 42 (63.6) 136 (55.3) 0.22
CPT-11, n (%) 8 (12.1) 52 (21.1) 0.09
CBDCA, n (%) 16 (24.2) 58 (23.6) 0.91
Oral intake of 5-FU, n (%) 39 (59.1) 116 (47.2) 0.08
  1. PS performance status, NEUT neutrophil, ULN upper limit of normal, NRS numerical rating score, L-OHP oxaliplatin, CPT-11 irinotecan, CBDCA carboplatin, SD standard deviation